Initiated Outperform X

NTRA Natera

RBC Capital Mkts

$251

Initiated Overweight X

NTRA Natera

Barclays

$200

Resumed Buy X

NTRA Natera

Jefferies

$142

Resumed Buy X

NTRA Natera

Craig Hallum

$117

Downgrades Strong Buy Outperform X

NTRA Natera

Raymond James

$68 $85

Reiterated Buy X

NTRA Natera

BTIG Research

$75 $85

Initiated Buy X

NTRA Natera

Guggenheim

$70

Initiated Outperform X

NTRA Natera

Wolfe Research

$70

Upgrades Outperform Strong Buy X

NTRA Natera

Raymond James

$68

Initiated Mkt Perform X

NTRA Natera

Bernstein

$48

Resumed Overweight X

NTRA Natera

JP Morgan

$85

Initiated Buy X

NTRA Natera

UBS

$76

Upgrades Mkt Perform Outperform X

NTRA Natera

Raymond James

$58

Initiated Outperform X

NTRA Natera

Credit Suisse

$70

Initiated Overweight X

NTRA Natera

Stephens

$54

Initiated Buy X

NTRA Natera

Goldman

$90

Resumed Overweight X

NTRA Natera

Piper Sandler

$110

Resumed Outperform X

NTRA Natera

Cowen

$150

Initiated Mkt Perform X

NTRA Natera

Raymond James

Initiated Overweight X

NTRA Natera

Wells Fargo

$110

Initiated Buy X

NTRA Natera

Truist

$143

Initiated Neutral X

NTRA Natera

JP Morgan

$26

Reiterated Overweight X

NTRA Natera

Piper Jaffray

$18 $21

NTRA  Natera, Inc.

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).